Indivisible Partners’s First Tracks Biotherapeutics TRAX Stock Holding History

Indivisible Partners’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$201K	Buy	+5,669	New	+$221K	0.01%	713

Other funds holding TRAX

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Indivisible Partners's TRAX Position: Q3 2026 in Review

Indivisible Partners opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 5,669 shares worth $201K. The stake represents 0.01% of the portfolio and ranks #713 among its holdings.

19 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

Indivisible Partners held 5,669 shares of First Tracks Biotherapeutics worth $201K as of Q3 2026.
First Tracks Biotherapeutics was a new Indivisible Partners position in Q3 2026.
First Tracks Biotherapeutics made up 0.01% of Indivisible Partners's portfolio in Q3 2026, its #713 holding.
19 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Indivisible Partners's 13F filing for Q3 2026, filed 26 Oct 2026.